{"id":390778,"date":"2017-12-18T00:00:00","date_gmt":"2017-12-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnemd0003-2017-biopharma-type-2-diabetes-unmet-need-injectables-us-eu\/"},"modified":"2026-04-22T05:25:36","modified_gmt":"2026-04-22T05:25:36","slug":"unnemd0003-2017-biopharma-type-2-diabetes-unmet-need-injectables-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnemd0003-2017-biopharma-type-2-diabetes-unmet-need-injectables-us-eu\/","title":{"rendered":"Type 2 Diabetes | Unmet Need | Injectables | US\/EU"},"content":{"rendered":"<p>Because no current therapy for type 2 diabetes offers disease-modifying capabilities, there is\u00a0high unmet need for drugs that can effectively control the disease. <abbr title=\"Decision Resources Group\">DRG<\/abbr>\u2019s Type 2 Diabetes Unmet Need 2017 focuses\u00a0on injectable agents: insulins and <abbr title=\"glucagon-like peptide\">GLP<\/abbr>-1 receptor agonists. In <abbr title=\"Decision Resources Group\">DRG<\/abbr>\u2019s view, currently marketed injectables have scope to further move up the treatment algorithm. Therefore, understanding physicians\u2019 perspectives on these products is increasingly important. In this content we reveal which drug attributes drive endocrinologists\u2019 prescribing and explore how current injectables compare across efficacy, safety, and delivery attributes.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for type 2 diabetes?<\/li>\n<li>What attributes are key influencers, which have limited impact, and which are hidden opportunities?<\/li>\n<li>How do current therapies perform on key treatment drivers and goals for type 2 diabetes?<\/li>\n<li>What are the prevailing areas of unmet need and opportunity in type 2 diabetes?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to <abbr title=\"United States\">U.S.<\/abbr> and European endocrinologists\u00a0for a hypothetical new type 2 diabetes\u00a0drug?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research: <\/strong>Survey of 60\u00a0<abbr title=\"United States\">U.S.<\/abbr> and 31\u00a0European endocrinologists\u00a0fielded in March 2017.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Lantus, Basaglar, Toujeo, Tresiba, Trulicity, Victoza<\/p>\n","protected":false},"template":"","class_list":["post-390778","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-type-1-diabetes","biopharma-therapy-areas-type-2-diabetes","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390778\/revisions"}],"predecessor-version":[{"id":393902,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390778\/revisions\/393902"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}